Applied Genetic Technologies (AGTC) 10-K2017 FY Annual report

Filed: 13 Sep 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: ACA, adrenal, affirmatively, algorithm, alpha, AMT, AMTI, apportionment, ASP, bifurcated, Bionic, bundled, canal, chain, choice, ChronosFP, CNS, cochlea, cyst, device, distinct, drawn, DSMC, easy, fatty, fidelity, fragile, ganglion, gland, graphic, green, horizon, house, indirect, inpatient, intact, intrathecal, Irish, Israeli, Kymriah, library, limb, longitudinal, manipulate, manipulation, memoranda, metabolism, microperimetry, Ministry, modestly, muscular, neuroprosthetic, NHP, optogenetic, Overview, penetration, Pennesi, preapproval, principle, Project, propriety, pure, quantitative, red, regular, repeal, RP, RPE, RPRG, runway, Senate, send, shortlist, Society, Sofia, spectrum, spinal, standalone, streamlined, surgeon, technique, temporal, topline, Trump, variability, variation, versatile, vivo, waive, weakly

Removed: abnormality, accommodate, accommodated, Acta, adenoviral, aggregating, al, Alaskan, amenable, Ann, Arbor, array, arrest, aspect, assembled, assigned, assumed, autosomal, Avastin, biochemical, biology, biopharmaceutical, black, blood, bottom, break, budgeted, burdensome, cardiac, carried, Casey, chart, chromatography, circular, closest, cocktail, College, compelling, complementing, concentrating, conceptually, constant, conversion, convert, correlation, cortex, decade, depict, detergent, discomfort, disposable, dollar, dry, dystrophy, effected, efficiency, emergence, enabled, encouraging, endothelial, engineering, episome, etiology, evolved, exacerbated, extinguished, Eylea, facilitating, factor, farthest, FDIC, figure, fill, filled, filter, flexibility, flexible, floor, formulate, frozen, gained, gel, Genentech, genome, Genzyme, German, grow, grown, Haim, harvested, heart, humor, impacted, implicated, indefinite, infect, inflammatory, inserted, instance, interfere, IPO, judgmental, Kellogg, Komaromy, LCA, leaving, Leber, left, linked, lux, macular, magnifying, manifestation, Marianne, mediated, Medicine, Michigan, middle, Min, minimally, mitigating, modality, modify, modifying, monkey, monogenic, moonlit, movement, muscle, navigated, NEI, neovascular, nerve, neurologic, noncancelable, oncology, Ophthalmologica, ophthalmologist, Oregon, outer, overallotment, paper, path, payload, PDGF, photodynamic, plagued, Portland, powerful, predictability, presence, procedure, productivity, prolonged, promise, purify, rationale, reading, reallocated, recessive, reclassification, redemption, referenced, Regeneron, reliably, resell, residual, reverse, routine, routinely, row, safest, sBHK, scenario, screen, selecting, sense, separable, serve, shear, shell, shorthaired, signal, Simultaneously, slightly, slower, solution, Southwest, sovereign, split, standpoint, stimulated, stimulation, stirred, supported, survive, tank, top, traced, tranche, transform, transformative, transmit, transmitted, unchanged, underserved, underway, underwriting, unintended, unusual, vascular, vast, VEGF, warrant, white, widely

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

AGTC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Applied Genetic Technologies Corporation (the “Company”) for the year ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his or her knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: September 13, 2017	By:	/s/ Susan B. Washer
		Susan B. Washer
		Chief Executive Officer and President (Principal Executive Officer)

Date: September 13, 2017	By:	/s/ William A. Sullivan
		William A. Sullivan
		Chief Financial Officer
		(Principal Financial Officer)

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Applied Genetic Technologies Corporation and will be retained by Applied Genetic Technologies Corporation and furnished to the Securities and Exchange Commission or its staff upon request.